Repligen Corporation (RGEN)

Repligen Corporation (RGEN) is a healthcare company (medical instruments & supplies) based in the United States. The share price is $162.51, down 0.17% on the day, which values the company at $10.39B. Price as of 17 Nov 2026, 17:23 UTC, from Yahoo Finance.

Key facts

Share price
$162.51−0.17% today
Market value
$10.39B
Forward P/E
61.3×
Funk Score
44/100
Against its own history
About its usual priceusual price $158.64
200-week average
$151.967% above
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

Repligen Corporation in more detail

RGEN trades at 61.3× next year's expected earnings, 12.9× sales. Measured against its own history, the price is 2% above what its usual multiples would imply ($158.64) — about its usual price. It sits 7% above its 200-week average of $151.96.

Over the last five fiscal years Repligen Corporation has compounded revenue 15.0% a year, earnings per share -5.0% a year, free cash flow 17.9% a year. Its Funk Score is 44 out of 100 (financial strength 5.6, profitability 3.3, growth 4.9, value 3.7, each out of 10).

In its favour: Altman Z in the safe zone; Strong Piotroski score. Worth checking: Thin interest cover; Low return on invested capital.

6 of the superinvestors tracked here hold RGEN, including Lee Ainslie (2.4% of the portfolio), Wallace Weitz (0.5% of the portfolio), Brandon Haley (0.4% of the portfolio).

Superinvestors holding RGEN

6 of the investors tracked here report a position in their latest 13F filing.

Compare

Health Care companies of similar size

Side by side:RGEN vs TECH (Repligen Corporation vs Bio-Techne)RGEN vs UHS (Repligen Corporation vs Universal Health Services)RGEN vs HALO (Repligen Corporation vs Halozyme Therapeutics)RGEN vs DVA (Repligen Corporation vs DaVita)RGEN vs KYMR (Repligen Corporation vs Kymera Therapeutics)

All health care companies by market valueLargest companies in the United StatesAll stocks A–Z

Repligen Corporation (RGEN): questions and answers

What is RGEN's PEG ratio?

Repligen Corporation's PEG ratio is 1.62 — its P/E divided by its expected earnings growth. Around 1 is the classic sign of a price that matches the growth; well above it means the growth is being paid for in advance.

What is Repligen Corporation's market cap?

Repligen Corporation is valued at $10.39B at a share price of $162.51.

Is RGEN overvalued or undervalued?

Against its own history, RGEN is about its usual price: the price is 2% above the $158.64 implied by the median multiples it has traded at (price / earnings, price / sales, price / book, price / free cash flow). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

Is RGEN above its 200-week moving average?

Yes. RGEN is 6.9% above its 200-week average of $151.96. Long-term investors watch that line because strong companies rarely trade below it for long.

How fast is Repligen Corporation growing?

Over the last five fiscal years Repligen Corporation's revenue grew 15.0% a year and its earnings per share -5.0% a year; over ten years revenue grew 24.3% a year.

Does RGEN pay a dividend?

Repligen Corporation does not currently pay a regular dividend.

Cite this page

Funkfolio, “Repligen Corporation (RGEN) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/RGEN

Underlying data: Yahoo Finance; company filings with the SEC.